;CTGTs and Rare Disease TherapiesDetermining sameness of cellular and gene therapy products for exclusivity and other regulatory purposesRead moreEvolving cybersecurity risk landscape for cell, tissue, and gene therapy companiesRead moreThe Unified Patent Court is a key forum for disputes concerning advanced therapy patentsRead moreCTGTs face increased competition by hospital exemption in EuropeRead moreFDA breaks new ground for rare disease approval pathwaysRead moreFDA's fast-evolving biosimilar and interchangeability frameworksRead moreFDA Breakthrough Devices Program driven by reimbursement benefitsRead moreAdvancing access to orphan drugs in Latin AmericaRead morePrevious pageNext page
